index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
6,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005829,phosphorylated ser473 akt,protein,modified,akt1,uniprot,p31749,cytoplasm,go:0005829,negative,i,decreased,ser473,,,,,['166'],nan,nan,these peptides significantly decreased the level of phosphorylated ser473 akt and,pmc4885839,1,10,11,1,21
73,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,kinase activation,,,epithelial-like,,human,['258'],nan,nan,egfrviv: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism,pmc3634975,1,10,11,1,21
74,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,i,amplification,,,,,,['245'],nan,nan,"        both cases shared amplification of egfr and an absence of idh mutations. pten was normal in case 1 and absent in case 2. mgmt methylation was 28.7% in case 1 and 9.9% in case 2. ki-67 proliferation marker was 5-20% in case 1 and 5-10% in case 2. case 1 had 5-10% p53 and case 2 had <5% p53. case 1 showed a 1p deletion with 19q intact, while case 2 had inconclusive status [table 1].",pmc4135538,1,10,11,1,21
85,egfr,protein,receptor,egfr,uniprot,p00533,plasma membrane,go:0005886,endothelial growth factor receptor,protein,,,uniprot,p00533,plasma membrane,go:0005886,positive,d,augmentation,,,glioblastoma,brain,human,['65'],nan,nan,"          local amplification, dislocation, and alteration of endothelial growth factor receptor is the most commonly occurring genetic aberrations in gbm. it accounts for 57% of the total gbm [16]. augmentation of egfr is mainly present in classical subtype of gbm [17].",pmc9519330,1,10,11,1,21
206,pdgfra,protein,,pdgfra,uniprot,p16234,plasma membrane,go:0005886,pdgfra,gene,,pdgfra,,,nucleus,go:0005634,positive,i,amplification,,,,glioblastoma,human,['51'],nan,nan,"in the last decade multiple genetic alterations have been reported in primary glioblastoma (gbm) [1]. among those alterations for which a pathogenic and clinical relevance have been recurrently suggested, amplification (i.e., at the dna level) and/or overexpression (i.e., at the rna level) of the epidermal growth factor receptor (egfr), cyclin dependent kinase 4 (cdk4), mouse double minute 4 (mdm4), and platelet-derived growth factor receptor alpha (pdgfra) genes, are included [2,3]. thus, gene amplification, and particularly egfr gene amplification, is currently considered a major driver of tumor progression with potential prognostic value for risk stratification of gbm [4].",pmc7016708,1,10,11,1,21
249,stat3,protein,,stat3,uniprot,p40763,cytoplasm,go:0005737,stat3,protein,,stat3,uniprot,p40763,cytoplasm,go:0005737,negative,d,phosphorylation,,gbm oncosphere,cancer cell,brain,human,['261'],nan,nan,"the 020913 and 060919 gbm oncosphere lines were treated for 24 hours with the rtk inhibitors either as single agents or in combination, to determine downstream changes in cancer-related signaling transduction. the cell lysates were analyzed for phosphorylation status of three major cell signaling pathways including akt, mapk and stat3 (figure 4). all the rtk inhibitors either as single agents or in combinations were able to block phosphorylation of akt. some drugs could only inhibit phosphorylation of either stat3 or mapk, but not both. the combination of gefitinib and sunitinib, and sunitinib and sorafenib were the only ones able to simultaneously block the phosphorylation of akt, mapk and stat3 in both of the gbm oncosphere lines. the inhibition of p-akt, p-mapk and p-stat3 by gefitinib and sunitinib as well as sunitinib and sorafenib correlated with the ability of these combinations to effectively inhibit gbm oncosphere growth, although this does not directly demonstrate mechanism.",pmc3462750,1,10,11,1,21
267,tkd-egfr (c-terminal kinase domain knockout),protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,tkd-egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,i,localization,cytosol,b82l,fibroblast,,mouse,['278'],nan,nan," a mutation of the epidermal growth factor receptor (egfr) that results in a tandem kinase domain duplication (tkd-egfr) has been described in glioblastoma multiforme biopsies and cell lines. although the tkd-egfr confers tumorigenicity, little is known about the molecular underpinnings of receptor dysregulation. therefore, we transfected b82l mouse fibroblast cells devoid of endogenous egfr to determine the molecular mechanisms of receptor activation when expressed in cells as well as the contribution of each duplicated kinase domain to receptor phosphorylation. the tkd-egfr displayed chronically elevated basal autophosphorylation at five known phosphotyrosine sites. the chronically phosphorylated tkd-egfr was also resistant to competitive inhibition of ligand-binding compared to wild-type-egfr (wt-egfr) and exhibited undetectable levels of basal dimerization, suggesting the tkd-egfr escapes known mechanisms of receptor down-regulation. immunofluorescence analyses revealed a substantial portion of the tkd-egfr resides in the cytosol in an activated state, although surface-localized subsets of the receptor retain ligand-responsiveness. kinase activity-deficient knockouts of the n-terminal or the c-terminal kinase domains generated tkd-egfrs that recapitulate the autophosphorylation/localization patterns of a constitutively activated receptor versus a wt-like egfr, respectively. investigation of the molecular activity of the tkd-egfr yields evidence for a unique mechanism of constitutive activity and dual kinase domain activation. ",pmc2820599,1,10,11,1,21
5,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,p27kip1,protein,,cdkn1b,uniprot,p42771,cytoplasm,go:0005737,positive,i,phosphorylation,,u87mg.egfrviii,glial,brain,human,['164'],nan,nan,"      a retrospective analysis of clinical trials found that of 40 patients with egfr amplification, those also expressing egfrviii had significantly shorter survival (0.839 years) than patients without (1.374 years), p = 0.0031 (13). considerable growth advantage has been observed in egfrviii transfected gbm cell lines (u87mg.egfrviii), when compared to wtegfr cell lines (28–30). this growth advantage is thought to result from an elevated proliferation rate coupled with a reduction in apoptosis (28). similar to egfr signaling, egfrviii activates the rtk/ras/pi3k pathway as a result of egfrviii expression (31, 32). this results in increased levels of phosphorylated akt and reduced levels of p27kip1, a cell cycle regulator that inhibits g1–s phase transition in cell lines (33). furthermore, abnormal spindle-like microcephaly-associated (aspm) protein expression has been described in the u87mg.egfrviii cells compared to parental u87mg cells (34). aspm promotes neural stem cell self-proliferation and hence it has been postulated the increased expression results in enhanced gbm progression by promoting cancer stem cell self-renewal (34).",pmc4310282,1,10,10,1,20
